Immune checkpoints

Bài viết trình bày xác định một số đặc điểm lâm sàng, cận lâm sàng của bệnh nhân viêm phổi liên quan thuốc điều trị ức chế điểm kiểm soát miễn dịch (Immune checkpoint inhibitor – ICI). Nghiên cứu hồi cứu mô tả cắt ngang trên 10 bệnh nhân có biến chứng viêm phổi liên quan ICI trong tổng số 61 ca được điều trị ICI tại khoa Ung bướu – Huyết học, Bệnh viện Đa khoa quốc tế Vinmec Times City năm 2023.

5p virichard 28-03-2024 16 3   Download

Immune-related adverse events (irAEs) are a major toxicity of immune checkpoint inhibitors. Studies have reported that pre-existing autoimmunity increases the risk of irAEs, but it remains unknown which clinical factors are linked to auto-immune disorders in cancer patients.

8p vielonmusk 21-01-2022 24 0   Download

Inhibitors targeting immune checkpoints, such as PD-1/PD-L1 and CTLA-4, have prolonged survival in small groups of non-small cell lung cancer (NSCLC) patients, but biomarkers predictive of the response to the immune checkpoint inhibitors (ICIs) remain rare.

19p vielonmusk 21-01-2022 15 1   Download

Advanced gastric cancer (AGC) is a disease with poor prognosis due to the current lack of effective therapeutic strategies. Immune checkpoint blockade treatments have shown effect responses in patient subgroups but biomarkers remain challenging. Traditional classifcation of gastric cancer (GC) is based on genomic profiling and molecular features.

13p vielonmusk 21-01-2022 10 1   Download

DNA repair deficiencies are characteristic of cancer and homologous recombination deficiency (HRD) is the most common. HRD sensitizes tumour cells to PARP inhibitors so it is important to understand the landscape of HRD across diferent solid tumour types. Methods: Germline and somatic BRCA mu

13p vielonmusk 21-01-2022 17 2   Download

Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their therapy outcome. PD-L1 expression and tumor mutational burden (TMB) were proven to be sometimes-unre‑ liable biomarkers.

13p vielonmusk 21-01-2022 13 1   Download

Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing.

10p vielonmusk 21-01-2022 16 0   Download

It has been postulated that patient’s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit, however, has not yet been explored using patient-level data, where potential confounder, as well as histologic type, can be accounted for. Here we investigated the association between sex and chemoimmunotherapy efficacy for non-small cell lung cancer (NSCLC) using a large, nation-wide dataset.

8p vielonmusk 21-01-2022 20 2   Download

Microsatellite instability (MSI) is a key marker for predicting the response of immune checkpoint inhibitors (ICIs) and for screening Lynch syndrome (LS). Aim: This study aimed to see the characteristics of cancers with high level of MSI (MSI-H) in genetic medicine and precision medicine.

12p vielonmusk 21-01-2022 10 0   Download

In this study, we conducted experiments to determine mRNA expression of above genes in PV patients by realtime-PCR and CA125 concentration by ELISA. Results showed that expression of klotho, LAG3, CTLA-4 and PD-1 genes was decreased in PV patients, indicating that the immune tolerance was inactivated in PV patients.

10p tamynhan10 24-10-2020 13 1   Download